Heterogeneity of follow-up procedures in French and Belgian patients with treated hereditary tyrosinemia type 1: results of a questionnaire and proposed guidelines.
Belgium; Disease Management; Follow-Up Studies; France; Humans; Kidney/metabolism; Liver/metabolism; Long-Term Care/methods; Practice Guidelines as Topic; Surveys and Questionnaires; Tyrosine/metabolism; Tyrosinemias/diet therapy/metabolism/therapy
Abstract :
[en] The 1991 introduction of 2-(2-nitro-4-trifluoro-methylbenzyol)-1,3 cyclohexanedione (NTBC) as a treatment for hereditary tyrosinemia type 1 (HT-1), a disorder of tyrosine catabolism, has radically modified the natural history of this disorder. Despite the dramatic improvements in survival, outcomes and quality of life seen with NTBC treatment, HT-1 remains a chronic disorder with several long-term complications, including, a persistent (albeit low) risk of hepatocellular carcinoma and suboptimal neuropsychological outcomes. There remain unsolved key-questions concerning the long-term outcomes of patients with HT-1, which closely depend on the quality of follow-up in these patients. In the absence of published guidelines, we investigated the follow-up methods used for French and Belgian patients with HT-1. A simple questionnaire providing a rapid overview of follow-up procedures was sent to the 19 physicians in charge of HT-1 patients treated with NTBC and low-tyrosine diet in France and Belgium. Several areas of heterogeneity (especially liver imaging, slit lamp examination, neuropsychological evaluation and maximal plasma tyrosine level accepted) were observed. In an attempt to improve long-term management and outcome of patients with HT-1, we proposed follow-up recommendations.
Heterogeneity of follow-up procedures in French and Belgian patients with treated hereditary tyrosinemia type 1: results of a questionnaire and proposed guidelines.
Ahmad S, Teckman JH, Lueder GT (2002) Corneal opacities associated with NTBC treatment. Am J Ophthalmol 134:266-268
Couce ML, Aldamiz-Echevarria L, Baldellou A et al. (2010) Recommendations and management of type I hereditary or hepatorenal tyrosinemia. An Pediatr (Barc) 73(5)279.e1-e4
De Laet C, Munoz VT, Jaeken J et al. (2011) Neuropsychological outcome of NTBC-treated patients with tyrosinaemia type 1. Dev Med Child Neurol 53:962-964
Ellis MK, Whitfield AC, Gowans LA et al. (1995) Inhibition of 4-hydroxyphenylpyruvate dioxygenase by 2-(2-nitro-4-trifluoromethylbenzoyl)- cyclohexane-1,3-dione and 2-(2-chloro-4-methanesul-fonylbenzoyl)-cyclohexane-1, 3-dione. Toxicol Appl Pharmacol 133:12-19
Gissen P, Preece MA, Willshaw HA, McKiernan PJ (2003) Ophthalmic follow-up of patients with tyrosinaemia type I on NTBC. J Inherit Metab Dis 26:13-16
Grompe M (2001) The pathophysiology and treatment of hereditary tyrosinemia type 1. Semin Liver Dis 21:563-571
Koelink CJ, van Hasselt P, van der Ploeg A et al. (2006) Tyrosinemia type I treated by NTBC: how does AFP predict liver cancer? Mol Genet Metab 89:310-315
Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B (1992) Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340:813-817
Mamunes P, Prince PE, Thornton NH, Hunt PA, Hitchcock ES (1976) Intellectual deficits after transient tyrosinemia in the term neonate. Pediatrics 57:675-680
Masurel-Paulet A, Poggi-Bach J, Rolland MO et al. (2008) NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis 31:81-87
McKiernan PJ (2006) Nitisinone in the treatment of hereditary tyrosi-naemia type 1. Drugs 66:743-750
Mohan N, McKiernan P, Preece MA et al. (1999) Indications and outcome of liver transplantation in tyrosinaemia type 1. Eur J Pediatr 158(Suppl 2):S49-S54
Sniderman King L, Trahms C, Scott CR (1993) Tyrosinemia Type 1.
van Spronsen FJ, Thomasse Y, Smit GP et al. (1994) Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology 20:1187-1191